Minireview: Tipping the balance: ligand-independent activation of steroid receptors

Molecular Endocrinology

Volumn 29, Issue 3, 2015, Pages 349-363

  Bennesch, Marcela A ^a   Picard, Didier ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; DOPAMINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INSULIN; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; NEU DIFFERENTIATION FACTOR; PROGESTERONE RECEPTOR; PROLACTIN; STAT3 PROTEIN; STEROID RECEPTOR; CYTOKINE; LIGAND;

PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANIMAL; BIOLOGICAL MODEL; HUMAN; METABOLISM;

AMINO ACIDS; ANIMALS; CYTOKINES; HUMANS; LIGANDS; MODELS, BIOLOGICAL; RECEPTORS, STEROID; SIGNAL TRANSDUCTION;

EID: 84923687668     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1315     Document Type: Review

References (187)

1. Robinson-Rechavi M, Carpentier AS, Duffraisse M, Laudet V. How many nuclear hormone receptors are there in the human genome? Trends Genet. 2001;17:554-556.
2. Tsai MJ, O’Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 1994;63:451-486.
3. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: The second decade. Cell. 1995;83:835-839.
4. Yamamoto KR. Steroid receptor regulated transcription of specific genes and gene networks. Annu Rev Genet. 1985;19:209-252.
5. Beato M, Truss M, Chávez S. Control of transcription by steroid hormones. Ann NY Acad Sci. 1996;784:93-123.
6. Evans RM, Mangelsdorf DJ. Nuclear receptors, RXR, and the big bang. Cell. 2014;157:255-266.
7. Stoica GE, Franke TF, Wellstein A, et al. Heregulin-β1 regulates the estrogen receptor-α gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene. 2005;24:1964.
8. Ferriere F, Habauzit D, Pakdel F, Saligaut C, Flouriot G. Unliganded estrogen receptor α promotes PC12 survival during serum starvation. PLoS One. 2013;8:e69081.
9. Sanchez M, Picard N, Sauve K, Tremblay A. Challenging estrogen receptor β with phosphorylation. Trends Endocrinol Metab. 2010;21:104-110.
10. Maggi A. Liganded and unliganded activation of estrogen receptor and hormone replacement therapies. Biochim Biophys Acta. 2011;1812:1054-1060.
11. Lamont KR, Tindall DJ. Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol. 2011;25: 897-907.
12. Anbalagan M, Huderson B, Murphy L, Rowan BG. Post-translational modifications of nuclear receptors and human disease. Nucl Recept Signal. 2012;10:e001.
13. Trevino LS, Weigel NL. Phosphorylation: A fundamental regulator of steroid receptor action. Trends Endocrinol Metab. 2013;24: 515-524.
14. Ignar-Trowbridge DM, Nelson KG, Bidwell MC, et al. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci USA. 1992;89: 4658-4662.
15. Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLachlan JA. Peptide growth factors elicit estrogen receptordependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol. 1993;7:992-998.
16. Zhang Y, Bai W, Allgood VE, Weigel NL. Multiple signaling pathways activate the chicken progesterone receptor. Mol Endocrinol. 1994;8:577-584.
17. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54:5474-5478.
18. Piotrowicz RS, Ding L, Maher P, Levin EG. Inhibition of cell migration by 24-kDa fibroblast growth factor-2 is dependent upon the estrogen receptor. J Biol Chem. 2001;276:3963-3970.
19. Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene. 2010;29:3208-3216.
20. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995;10: 2435-2446.
21. Labriola L, Salatino M, Proietti CJ, et al. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Mol Cell Biol. 2003;23: 1095-1111.
22. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 1999;5:280-285.
23. Aronica SM, Katzenellenbogen BS. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol. 1993;7:743-752.
24. Ma ZQ, Santagati S, Patrone C, Pollio G, Vegeto E, Maggi A. Insulin-like growth factors activate estrogen receptor to control the growth and differentiation of the human neuroblastoma cell line SK-ER3. Mol Endocrinol. 1994;8:910-918.
25. Newton CJ, Buric R, Trapp T, Brockmeier S, Pagotto U, Stalla GK. The unliganded estrogen receptor (ER) transduces growth factor signals. J Steroid Biochem Mol Biol. 1994;48:481-486.
26. Power RF, Mani SK, Codina J, Conneely OM, O’Malley BW. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science. 1991;254:1636-1639.
27. Lee SO, Lou W, Hou M, Onate SA, Gao AC. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene. 2003;22:7981-7988.
28. Speirs V, Kerin MJ, Walton DS, Newton CJ, Desai SB, Atkin SL. Direct activation of oestrogen receptor-α by interleukin-6 in primary cultures of breast cancer epithelial cells. Br J Cancer. 2000; 82:1312-1316.
29. Hobisch A, Eder IE, Putz T, et al. Interleukin-6 regulates prostatespecific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998;58:4640-4645.
30. Chen T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. 2000;60:2132-2135.
31. Seaton A, Scullin P, Maxwell PJ, et al. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis. 2008;29:1148-1156.
32. Kasina S, Macoska JA. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol. 2012;351:249-263.
33. Gori I, Pellegrini C, Staedler D, Russell R, Jan C, Canny GO. Tumor necrosis factor-α activates estrogen signaling pathways in endometrial epithelial cells via estrogen receptor α. Mol Cell Endocrinol. 2011;345:27-37.
34. Demay F, De Monti M, Tiffoche C, Vaillant C, Thieulant ML. Steroid-independent activation of ER by GnRH in gonadotrope pituitary cells. Endocrinology. 2001;142:3340-3347.
35. Turgeon JL, Waring DW. Activation of the progesterone receptor by the gonadotropin-releasing hormone self-priming signaling pathway. Mol Endocrinol. 1994;8:860-869.
36. Catalano S, Mauro L, Marsico S, et al. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor α in MCF-7 cells. J Biol Chem. 2004;279:19908-19915.
37. Gonzalez L, Zambrano A, Lazaro-Trueba I, et al. Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene. 2009;28:1298-1308.
38. Nakhla AM, Romas NA, Rosner W. Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone-binding globulin. J Biol Chem. 1997;272:6838-6841.
39. Della Torre S, Rando G, Meda C, et al. Amino acid-dependent activation of liver estrogen receptor α integrates metabolic and reproductive functions via IGF-1. Cell Metab. 2011;13:205-214.
40. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997;88:405-415.
41. Neuman E, Ladha MH, Lin N, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol. 1997;17:5338-5347.
42. Trowbridge JM, Rogatsky I, Garabedian MJ. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci USA. 1997;94:10132-10137.
43. Pierson-Mullany LK, Lange CA. Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol. 2004;24:10542-10557.
44. Tolon RM, Castillo AI, Jimenez-Lara AM, Aranda A. Association with Ets-1 causes ligand- and AF2-independent activation of nuclear receptors. Mol Cell Biol. 2000;20:8793-8802.
45. Cho J, Bahn JJ, Park M, Ahn W, Lee YJ. Hypoxic activation of unoccupied estrogen-receptor-α is mediated by hypoxia-inducible factor-1 α. J Steroid Biochem Mol Biol. 2006;100:18-23.
46. Guo JP, Shu SK, Esposito NN, Coppola D, Koomen JM, Cheng JQ. IKK_ phosphorylation of estrogen receptor α Ser-167 and contribution to tamoxifen resistance in breast cancer. J Biol Chem. 2010;285:3676-3684.
47. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996;15:2174-2183.
48. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL. Mitogen-activated protein kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol. 1999;19:5143-5154.
49. Wang RA, Mazumdar A, Vadlamudi RK, Kumar R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-α and promotes hyperplasia in mammary epithelium. EMBO J. 2002;21:5437-5447.
50. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J Biol Chem. 2001;276:9817-9824.
51. Michalides R, Griekspoor A, Balkenende A, et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. Cancer Cell. 2004;5:597-605.
52. Martin MB, Franke TF, Stoica GE, et al. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology. 2000;141:4503-4511.
53. Sun M, Paciga JE, Feldman RI, et al. Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor α (ERα) via interaction between ERα and PI3K. Cancer Res. 2001;61:5985-5991.
54. Ma Y, Hu C, Riegel AT, Fan S, Rosen EM. Growth factor signal ing pathways modulate BRCA1 repression of estrogen receptor-α activity. Mol Endocrinol. 2007;21:1905-1923.
55. De Servi B, Hermani A, Medunjanin S, Mayer D. Impact of PKC_ on estrogen receptor localization and activity in breast cancer cells. Oncogene. 2005;24:4946-4955.
56. Feng W, Webb P, Nguyen P, et al. Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway. Mol Endocrinol. 2001;15:32-45.
57. Wei C, Cao Y, Yang X, et al. Elevated expression of TANKbinding kinase 1 enhances tamoxifen resistance in breast cancer. Proc Natl Acad Sci USA. 2014;111:E601-E610.
58. Carascossa S, Dudek P, Cenni B, Briand PA, Picard D. CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor α by cAMP. Genes Dev. 2010;24: 708-719.
59. Denner LA, Weigel NL, Maxwell BL, Schrader WT, O’Malley BW. Regulation of progesterone receptor-mediated transcription by phosphorylation. Science. 1990;250:1740-1743.
60. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem. 1996;271:19900-19907.
61. Patrone C, Ma ZQ, Pollio G, Agrati P, Parker MG, Maggi A. Cross-coupling between insulin and estrogen receptor in human neuroblastoma cells. Mol Endocrinol. 1996;10:499-507.
62. Ignar-Trowbridge DM, Pimentel M, Teng CT, Korach KS, McLachlan JA. Cross talk between peptide growth factor and estrogen receptor signaling systems. Environ Health Perspect. 1995;103(suppl 7):35-38.
63. Darne C, Veyssiere G, Jean C. Phorbol ester causes ligand-independent activation of the androgen receptor. Eur J Biochem. 1998; 256:541-549.
64. Divekar SD, Storchan GB, Sperle K, et al. The role of calcium in the activation of estrogen receptor-α. Cancer Res. 2011;71:1658-1668.
65. Bratton MR, Antoon JW, Duong BN, et al. Gαo potentiates estrogen receptor α activity via the ERK signaling pathway. J Endocrinol. 2012;214:45-54.
66. Moore RL, Faller DV. SIRT1 represses estrogen-signaling, ligandindependent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol. 2013;216:273-285.
67. Martin MB, Reiter R, Pham T, et al. Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology. 2003;144: 2425-2436.
68. Stoica A, Pentecost E, Martin MB. Effects of selenite on estrogen receptor-α expression and activity in MCF-7 breast cancer cells. J Cell Biochem. 2000;79:282-292.
69. Stoica A, Katzenellenbogen BS, Martin MB. Activation of estrogen receptor-α by the heavy metal cadmium. Mol Endocrinol. 2000;14:545-553.
70. Stoica A, Pentecost E, Martin MB. Effects of arsenite on estrogen receptor-α expression and activity in MCF-7 breast cancer cells. Endocrinology. 2000;141:3595-3602.
71. Lee K, Liu Y, Mo JQ, Zhang J, Dong Z, Lu S. Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer. BMC Cancer. 2008;8:158.
72. Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol Endocrinol. 2008;22: 597-608.
73. Gehm BD, McAndrews JM, Jordan VC, Jameson JL. EGF activates highly selective estrogen-responsive reporter plasmids by an ER-independent pathway. Mol Cell Endocrinol. 2000;159: 53-62.
74. Tremblay A, Tremblay GB, Labrie F, Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol Cell. 1999;3:513-519.
75. Tremblay A, Giguere V. Contribution of steroid receptor coactivator-1 and CREB binding protein in ligand-independent activity of estrogen receptor β. J Steroid Biochem Mol Biol. 2001;77:19-27.
76. Sauve K, Lepage J, Sanchez M, Heveker N, Tremblay A. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res. 2009;69:5793-5800.
77. Vivar OI, Saunier EF, Leitman DC, Firestone GL, Bjeldanes LF. Selective activation of estrogen receptor-β target genes by 3,3_-diindolylmethane. Endocrinology. 2010;151:1662-1667.
78. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci USA. 1993;90:4441-4445.
79. Sartorius CA, Groshong SD, Miller LA, et al. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res. 1994;54:3868-3877.
80. Sartorius CA, Tung L, Takimoto GS, Horwitz KB. Antagonistoccupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J Biol Chem. 1993;268:9262-9266.
81. Kotitschke A, Sadie-Van Gijsen H, Avenant C, Fernandes S, Hapgood JP. Genomic and nongenomic cross talk between the gonadotropin- releasing hormone receptor and glucocorticoid receptor signaling pathways. Mol Endocrinol. 2009;23:1726-1745.
82. Verhoog NJ, Du Toit A, Avenant C, Hapgood JP. Glucocorticoidindependent repression of tumor necrosis factor (TNF) α-stimulated interleukin (IL)-6 expression by the glucocorticoid receptor: a potential mechanism for protection against an excessive inflammatory response. J Biol Chem. 2011;286:19297-19310.
83. Lupien M, Meyer CA, Bailey ST, et al. Growth factor stimulation induces a distinct ER(α) cistrome underlying breast cancer endocrine resistance. Genes Dev. 2010;24:2219-2227.
84. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992;24:85-95.
85. Picard D. Molecular mechanisms of cross-talk between growth factors and nuclear receptor signaling. Pure Appl Chem. 2003;75: 1743-1756.
86. Berno V, Amazit L, Hinojos C, et al. Activation of estrogen receptor- α by E2 or EGF induces temporally distinct patterns of largescale chromatin modification and mRNA transcription. PLoS One. 2008;3:e2286.
87. Guo Z, Dai B, Jiang T, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell. 2006;10:309-319.
88. Kraus S, Gioeli D, Vomastek T, Gordon V, Weber MJ. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res. 2006;66:11047-11054.
89. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235: 177-182.
90. Borg A, Baldetorp B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 1994;81:137-144.
91. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol. 2002; 79:216-223.
92. Pancholi S, Lykkesfeldt AE, Hilmi C, et al. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-re-sistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr Relat Cancer. 2008;15:985-1002.
93. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96: 926-935.
94. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA. 1999;96:5458-5463.
95. Holmes WE, Sliwkowski MX, Akita RW, et al. Identification of heregulin, a specific activator of p185erbB2. Science. 1992;256: 1205-1210.
96. Falls DL, Rosen KM, Corfas G, Lane WS, Fischbach GD. ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. Cell. 1993;72:801-815.
97. Loi S, Sotiriou C, Haibe-Kains B, et al. Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med Genomics. 2009;2:37.
98. Mahajan NP, Liu Y, Majumder S, et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA. 2007;104:8438-8443.
99. Proietti CJ, Rosemblit C, Beguelin W, et al. Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth. Mol Cell Biol. 2009;29: 1249-1265.
100. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem. 1978;253:2769-2776.
101. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-34.
102. Straus DS, Takemoto CD. Effect of fasting on insulin-like growth factor-I (IGF-1) and growth hormone receptor mRNA levels and IGF-1 gene transcription in rat liver. Mol Endocrinol. 1990;4:91-100.
103. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc. 2001;60: 91-106.
104. Moses AC, Young SC, Morrow LA, O’Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes. 1996;45:91-100.
105. Cheng CM, Reinhardt RR, Lee WH, Joncas G, Patel SC, Bondy CA. Insulin-like growth factor 1 regulates developing brain glucose metabolism. Proc Natl Acad Sci USA. 2000;97:10236-10241.
106. Gauguin L, Klaproth B, Sajid W, et al. Structural basis for the lower affinity of the insulin-like growth factors for the insulin receptor. J Biol Chem. 2008;283:2604-2613.
107. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol. 2011;25:516-528.
108. Gaben AM, Sabbah M, Redeuilh G, Bedin M, Mester J. Ligandfree estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells. BMC Cancer. 2012;12:291.
109. Snyder GL, Fienberg AA, Huganir RL, Greengard P. A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J Neurosci. 1998;18:10297-10303.
110. Gomes AR, Cunha P, Nuriya M, et al. Metabotropic glutamate and dopamine receptors co-regulate AMPA receptor activity through PKA in cultured chick retinal neurones: effect on GluR4 phosphorylation and surface expression. J Neurochem. 2004;90: 673-682.
111. Beyer C, Canchola E, Larsson K. Facilitation of lordosis behavior in the ovariectomized estrogen primed rat by dibutyryl cAMP. Physiol Behav. 1981;26:249-251.
112. Beyer C, Canchola E. Facilitation of progesterone induced lordosis behavior by phosphodiesterase inhibitors in estrogen primed rats. Physiol Behav. 1981;27:731-733.
113. Mani SK, Allen JM, Clark JH, Blaustein JD, O’Malley BW. Convergent pathways for steroid hormone- and neurotransmitter-induced rat sexual behavior. Science. 1994;265:1246-1249.
114. Apostolakis EM, Garai J, Fox C, et al. Dopaminergic regulation of progesterone receptors: brain D5 dopamine receptors mediate induction of lordosis by D1-like agonists in rats. J Neurosci. 1996; 16:4823-4834.
115. Mani SK, Allen JM, Lydon JP, et al. Dopamine requires the unoccupied progesterone receptor to induce sexual behavior in mice. Mol Endocrinol. 1996;10:1728-1737.
116. Olesen KM, Auger AP. Dopaminergic activation of estrogen receptors induces fos expression within restricted regions of the neonatal female rat brain. PLoS One. 2008;3:e2177.
117. Lee YS, Choi I, Ning Y, et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer. 2012;106:1833-1841.
118. Sullivan NJ, Sasser AK, Axel AE, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009;28:2940-2947.
119. Degeorges A, Tatoud R, Fauvel-Lafeve F, et al. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer. 1996;68:207-214.
120. Ritchie CK, Andrews LR, Thomas KG, Tindall DJ, Fitzpatrick LA. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology. 1997;138: 1145-1150.
121. Douglas AM, Goss GA, Sutherland RL, et al. Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene. 1997;14:661-669.
122. Stork PJ, Schmitt JM. Cross talk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 2002;12:258-266.
123. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem. 2002;277: 7076-7085.
124. Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. J Urol. 2000; 164:722-725.
125. Chen CD, Sawyers CL. NF-_B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol. 2002;22:2862-2870.
126. Lee SO, Lou W, Nadiminty N, Lin X, Gao AC. Requirement for NF-(_)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate. 2005;64:160-167.
127. Lee SO, Chun JY, Nadiminty N, Lou W, Feng S, Gao AC. Interleukin-4 activates androgen receptor through CBP/p300. Prostate. 2009;69:126-132.
128. Shyamala G, Chou YC, Louie SG, Guzman RC, Smith GH, Nandi S. Cellular expression of estrogen and progesterone receptors in mammary glands: regulation by hormones, development and aging. J Steroid Biochem Mol Biol. 2002;80:137-148.
129. Brisken C, O’Malley B. Hormone action in the mammary gland. Cold Spring Harb Perspect Biol. 2010;2:a003178.
130. Gutzman JH, Miller KK, Schuler LA. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor α and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J Steroid Biochem Mol Biol. 2004; 88:69-77.
131. O’Leary KA, Jallow F, Rugowski DE, et al. Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo. Endocrinology. 2013;154:4483-4492.
132. Wu G. Functional amino acids in growth, reproduction, and health. Adv Nutr. 2010;1:31-37.
133. Wu G, Bazer FW, Davis TA, et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids. 2009;37:153-168.
134. Takeda K, Toda K, Saibara T, et al. Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency. J Endocrinol. 2003;176:237-246.
135. Venken K, Schuit F, Van Lommel L, et al. Growth without growth hormone receptor: estradiol is a major growth hormone-independent regulator of hepatic IGF-1 synthesis. J Bone Miner Res. 2005; 20:2138-2149.
136. Ciana P, Raviscioni M, Mussi P, et al. In vivo imaging of transcriptionally active estrogen receptors. Nat Med. 2003;9:82-86.
137. Gillett C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994;54:1812-1817.
138. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat. 2003;78:323-335.
139. Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK, Sutherland RL. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol. 1993;13:3577-3587.
140. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev. 1998;12:3488-3498.
141. McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci USA. 1999;96:5382-5387.
142. Casimiro MC, Wang C, Li Z, et al. Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Mol Endocrinol. 2013; 27:1415-1428.
143. Rogatsky I, Trowbridge JM, Garabedian MJ. Potentiation of human estrogen receptor α transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem. 1999;274:22296-22302.
144. Bindels EM, Lallemand F, Balkenende A, Verwoerd D, Michalides R. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells. Oncogene. 2002;21:8158-8165.
145. Sutherland RL, Lee CS, Feldman RS, Musgrove EA. Regulation of breast cancer cell cycle progression by growth factors, steroids and steroid antagonists. J Steroid Biochem Mol Biol. 1992;41:315-321.
146. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer. 2003;10: 179-186.
147. Sabbah M, Courilleau D, Mester J, Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP responselike element. Proc Natl Acad Sci USA. 1999;96:11217-11222.
148. Gburcik V, Picard D. The cell-specific activity of the estrogen receptor α may be fine-tuned by phosphorylation-induced structural gymnastics. Nucl Recept Signal. 2006;4:e005.
149. Gburcik V, Bot N, Maggiolini M, Picard D. SPBP is a phosphoserine-specific repressor of estrogen receptor α. Mol Cell Biol. 2005;25:3421-3430.
150. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem. 1994;269:4458-4466.
151. Chen D, Pace PE, Coombes RC, Ali S. Phosphorylation of human estrogen receptor α by protein kinase A regulates dimerization. Mol Cell Biol. 1999;19:1002-1015.
152. Zwart W, Griekspoor A, Berno V, et al. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERα towards co-activator SRC-1. EMBO J. 2007;26:3534-3544.
153. Tharakan R, Lepont P, Singleton D, Kumar R, Khan S. Phosphorylation of estrogen receptor α, serine residue 305 enhances activity. Mol Cell Endocrinol. 2008;295:70-78.
154. Giordano C, Cui Y, Barone I, et al. Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor α and its phosphorylation at serine 305. Breast Cancer Res Treat. 2010;119:71-85.
155. Fenne IS, Hoang T, Hauglid M, Sagen JV, Lien EA, Mellgren G. Recruitment of coactivator glucocorticoid receptor interacting protein 1 to an estrogen receptor transcription complex is regulated by the 3_,5_-cyclic adenosine 5_-monophosphate-dependent protein kinase. Endocrinology. 2008;149:4336-4345.
156. Lei H, Venkatakrishnan A, Yu S, Kazlauskas A. Protein kinase A-dependent translocation of Hsp90α impairs endothelial nitricoxide synthase activity in high glucose and diabetes. J Biol Chem. 2007;282:9364-9371.
157. Picard D. Chaperoning steroid hormone action. Trends Endocrinol Metab. 2006;17:229-235.
158. Sun Y, Chung HH, Woo AR, Lin VC. Protein arginine methyltransferase 6 enhances ligand-dependent and -independent activity of estrogen receptor α via distinct mechanisms. Biochim Biophys Acta. 2014;1843:2067-2078.
159. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-_B activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999;401:82-85.
160. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-_B1 precursor protein and the activation of NF-_B. Cell. 1994;78: 773-785.
161. Chen D, Ma H, Hong H, et al. Regulation of transcription by a protein methyltransferase. Science. 1999;284:2174-2177.
162. Chen D, Huang SM, Stallcup MR. Synergistic, p160 coactivatordependent enhancement of estrogen receptor function by CARM1 and p300. J Biol Chem. 2000;275:40810-40816.
163. Cascio S, Bartella V, Garofalo C, Russo A, Giordano A, Surmacz E. Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells. J Biol Chem. 2007;282: 3498-3506.
164. de Leeuw R, Flach K, Bentin Toaldo C, et al. PKA phosphorylation redirects ERα to promoters of a unique gene set to induce tamoxifen resistance. Oncogene. 2013;32:3543-3551.
165. Dudek P, Picard D. Genomics of signaling cross talk of estrogen receptor α in breast cancer cells. PLoS One. 2008;3:e1859.
166. Apostolakis EM, Garai J, Lohmann JE, Clark JH, O’Malley BW. Epidermal growth factor activates reproductive behavior independent of ovarian steroids in female rodents. Mol Endocrinol. 2000; 14:1086-1098.
167. Olesen KM, Jessen HM, Auger CJ, Auger AP. Dopaminergic activation of estrogen receptors in neonatal brain alters progestin receptor expression and juvenile social play behavior. Endocrinology. 2005;146:3705-3712.
168. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrineloop. Am J Pathol. 1995;146:695-705.
169. Kurtz A, Bristol LA, Toth BE, Lazar-Wesley E, Takacs L, Kacsoh B. Mammary epithelial cells of lactating rats express prolactin messenger ribonucleic acid. Biol Reprod. 1993;48:1095-1103.
170. Curtis SW, Washburn T, Sewall C, et al. Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc Natl Acad Sci USA. 1996;93:12626-12630.
171. Klotz DM, Hewitt SC, Ciana P, et al. Requirement of estrogen receptor-α in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor crosstalk. J Biol Chem. 2002;277:8531-8537.
172. Sinkevicius KW, Burdette JE, Woloszyn K, et al. An estrogen receptor-α knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology. 2008;149:2970-2979.
173. Winuthayanon W, Hewitt SC, Orvis GD, Behringer RR, Korach KS. Uterine epithelial estrogen receptor α is dispensable for proliferation but essential for complete biological and biochemical responses. Proc Natl Acad Sci USA. 2010;107:19272-19277.
174. Sinkevicius KW, Laine M, Lotan TL, Woloszyn K, Richburg JH, Greene GL. Estrogen-dependent and -independent estrogen receptor-α signaling separately regulate male fertility. Endocrinology. 2009;150:2898-2905.
175. Bridgham JT, Eick GN, Larroux C, et al. Protein evolution by molecular tinkering: diversification of the nuclear receptor superfamily from a ligand-dependent ancestor. PLoS Biol. 2010;8.
176. Markov GV, Laudet V. Origin and evolution of the ligandbinding ability of nuclear receptors. Mol Cell Endocrinol. 2011;334:21-30.
177. Thornton JW. Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. Proc Natl Acad Sci USA. 2001;98:5671-5676.
178. Thornton JW, Need E, Crews D. Resurrecting the ancestral steroid receptor: ancient origin of estrogen signaling. Science. 2003; 301:1714-1717.
179. Keay J, Bridgham JT, Thornton JW. The Octopus vulgaris estrogen receptor is a constitutive transcriptional activator: evolutionary and functional implications. Endocrinology. 2006;147:3861-3869.
180. Paris M, Pettersson K, Schubert M, et al. An amphioxus orthologue of the estrogen receptor that does not bind estradiol: insights into estrogen receptor evolution. BMC Evol Biol. 2008;8:219.
181. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA. Interdomain communication regulating ligand binding by PPAR-γ. Nature. 1998;396:377-380.
182. Lazennec G, Canaple L, Saugy D, Wahli W. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol Endocrinol. 2000;14:1962-1975.
183. Sablin EP, Krylova IN, Fletterick RJ, Ingraham HA. Structural basis for ligand-independent activation of the orphan nuclear receptor LRH-1. Mol Cell. 2003;11:1575-1585.
184. Khan SA, Park SW, Huq MD, Wei LN. Ligand-independent orphan receptor TR2 activation by phosphorylation at the DNAbinding domain. Proteomics. 2006;6:123-130.
185. Reid G, Hubner MR, Métivier R, et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell. 2003; 11:695-707.
186. Caizzi L, Ferrero G, Cutrupi S, et al. Genome-wide activity of unliganded estrogen receptor-α in breast cancer cells. Proc Natl Acad Sci USA. 2014;111:4892-4897.
187. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox M, Leitman D. Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell. 2006;21:555-564.